BSEBoard Meeting3d ago · 5 Aug 2026, 04:09 pm

Bal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 and other ....

Bal Pharma Ltd · 524824

✦ AI SummaryResults

Bal Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve the Unaudited (Standalone and Consolidated) Financial Statements for the first quarter ended 30th June 2026 and other general business matters.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Bal Pharma Ltd - 524824 - Board Meeting Intimation for Considering Inter-Alia The Unaudited (Standalone And Consolidated) Financial Statements Of The Company For The First Quarter Ended 30Th June 2026 And Other General Business Matters

Attachments (1)

📄

99e6bb65-f2d6-4f44-b101-4fc492b29f2a.pdf

pdf

Download →
View document text
To To Date: August 05, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J. Towers, Bandra Kurla Complex, Bandra (E), Dalal Street, Mumbai-400051 Mumbai – 400001 Symbol: BALPHARMA Scrip Code: 524824 Sub: Prior Intimation of Board Meeting pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/Madam, Pursuant to Regulation 29 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of the Board of Directors of Bal Pharma Limited is scheduled to be held on Wednesday, August 12, 2026, inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026 (Q1/2026-27) and such other matters as may be considered necessary with the permission of the Chair. Please takes this intimation on your records Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681